
🫀IC fellow at Mayo Clinic Rochester @MayoClinicCV Former Chief cardiology fellow @Beaumontcards | IM @OUWB | MD @ UJ_MED 🇯🇴 |Researcher| Views my own
Joined February 2021
- Tweets595
- Following262
- Followers713
- Likes1.5K
Pinned Tweet
Truly honored and thrilled to have matched at Mayo Clinic for interventional cardiology fellowship! #IC @MayoClinic Grateful to my mentors and everyone who supported me 🫀
#Match2026 #Cardiology #cardiotwitter @MayoCVFellows
Looking for a practical guide to bifurcation PCI? 📖
The SCAI PCI for Coronary Bifurcation Lesions ebook brings together leading experts to cover:
• Provisional vs. two-stent strategies
• IVUS and OCT optimization
• Left main bifurcation PCI
• DK Crush, Culotte, TAP, and more
Plus procedural technique videos demonstrating key approaches.
Download for free today ➡️ scai.org/publications/ebooks…
#InterventionalCardiology #CardioX #CardioEd #PCI @DrMauricioCohen @KateKearney4 @ArasiMaran
Stop by our sessions at #TCT2026 for two excellent talks on PCI of non-culprit lesions in STEMI and the role of vulnerable plaque detection! 🫀
@TCTMD @TCTConference @crfheart #MedTwitter #cardiotwitter @RyanMadderMD
Luai Madanat, MD retweeted
This is huge accomplishment!!!
Congratulations to @SCAI and @DrMauricioCohen
A lot of effort went into putting this together!!!
Download the book here:
scaipro.scai.org/URL/Bifuric…
Luai Madanat, MD retweeted
Please take a look at the tables to answer those 3 important questions guided by clinical evidence:
1. Yes to complete revascularization, but not all in the same setting during index STEMI.
2. Stage the second procedure before hospital discharge and do not wait for 4-6 weeks.
3. Use physiological guidance with FFR to choose which non culprit lesions to treat
We need more trials in this space of older patients.
See tables below and full link to the piece is here:
sciencedirect.com/science/ar…
@GianlucaCampo78 @SimoneBiscaglia @MichaelGNanna
Complete, But Not All at Once: Older Adults and Timing of Nonculprit Revascularization in STEMI: @JACCJournals
🥸 @MichaelGNanna and I wrote an editorial in JACC: Cardiovascular Interventions on the 3 questions every interventionalist faces after opening the culprit vessel in an older adult with STEMI and multivessel disease:
1️⃣ Should the nonculprit lesions be revascularized at all?
2️⃣ If so, when?
3️⃣ Which lesions actually need treatment?
Of course, based on clinical trial data: here is the summary
👇👇👇
Luai Madanat, MD retweeted
Complete, But Not All at Once: Older Adults and Timing of Nonculprit Revascularization in STEMI: @JACCJournals
🥸 @MichaelGNanna and I wrote an editorial in JACC: Cardiovascular Interventions on the 3 questions every interventionalist faces after opening the culprit vessel in an older adult with STEMI and multivessel disease:
1️⃣ Should the nonculprit lesions be revascularized at all?
2️⃣ If so, when?
3️⃣ Which lesions actually need treatment?
Of course, based on clinical trial data: here is the summary
👇👇👇
Luai Madanat, MD retweeted
In 4,398 pts w/out diagnostic ST elevation, the OMI/NOMI approach selected more pts for early invasive management vs conventional very-high-risk #NSTEMI criteria (45.4% vs 13.6%) and identified acute coronary occlusion sooner (35.1% vs 16.7%).
#JACCINT
bit.ly/3VTiqbl
Luai Madanat, MD retweeted
Reverse hairpin bend wiring technique #cardiotwitter #cardiox #MedTwitter @SCAI @ACCinTouch @AHAScience
Luai Madanat, MD retweeted
How should we treat patients with MAC-related MV dysfunction who are not candidates for surgery or M-TEER? In the ENCIRCLE MAC Registry, transseptal TMVR was associated with sustained MR reduction and meaningful improvements in symptoms and quality of life through 1 year. TS TMVR may represent a viable treatment pathway for this challenging patient population. @MayoClinicCV
Transseptal Transcatheter Mitral Valve Replacement for Mitral Annular … sciencedirect.com/science/ar…
Luai Madanat, MD retweeted
Web flow disruptor +/- stent. Here’s the link. Lesion in is not surgically accessible. jacc.org/doi/10.1016/j.jcin.…
Luai Madanat, MD retweeted
Time for #CardiogenicShock guidelines?
Our @JACCJournals #JACCAdvances State-of-the-Art Review: Evolving evidence across CS phenotypes, hemodynamics & #MCS & where guidance needs to evolve.
👉 jacc.org/doi/10.1016/j.jacad…
Shaped by expertise & insights of an all 🌟 coauthor team
Luai Madanat, MD retweeted
💊 "Aspirin Withdrawal in Patients With Coronary Artery Disease"
(2026 JACC STATE-OF-THE-ART REVIEW)
jacc.org/doi/10.1016/j.jacc.…
Luai Madanat, MD retweeted
The Rise of the Solo TAVR Operator: Alone, Unarmed, and Unafraid sciencedirect.com/science/ar…
Written before CMS finalized its new TAVR NCD - I think CMS got some of it right, and one big thing wrong.
Braasch et al looked at 400K Medicare TAVRs, 2016 to 2024. Surgical bailout in 0.56%, falling from 0.92% to 0.40%. Hospital SAVR volume, whether low, intermediate, or high, was not associated with mortality among patients requiring salvage surgery.
The absence of an on-site surgeon is not the absence of rescue. Transfer systems exist. A growing share of catastrophic complications, including contained annular injury, tamponade, and device embolization, are now rescued in the cath lab, far from the OR.
We have run this experiment before - PCI required on-site surgery on the same theory. CPORT-E: over 18k patients, 6-week mortality 0.9% vs 0.8%. MASS COMM: emergency surgery in 0.1% to 0.3%. PCI without on-site surgery became standard. Systems of care exists across the spectrum of CV care: cardiogenic shock, PE care etc.
What CMS got right in the final NCD: TAVR may be performed by a single operator. The mandated dual-specialty evaluation is dropped and only the operator's visit is required. Hospital procedural volume requirements are removed. Asymptomatic severe AS is now covered under CED.
Where CMS got it wrong: on-site cardiac surgery is retained. It compels the backup that is so rarely needed. A system of care with straightforward TAVRs being performed by ICs in non-surgical sites with affiliations for complex/transfers would've balanced access.
However, CMS & cardiac societies chose politics over patients in the end.
Proof: no requirement for on-site EP, though permanent pacing is the most common service after TAVR. No requirement for vascular surgery - much more valuable to a TAVR operator than CV surgery. The mandate is kept to protect physicians not patients.
Morevover, medicare imposes no minimum-volume condition on SAVR, despite a median annual surgeon volume of 16 cases. Volume, staffing and heart team requirements get framed as safeguards of quality. But they are absent for the surgical equivalent.
Let's be honest - that framing is a pretext for protecting case volume, referral patterns, and established programs. Legitimate interests, just not the ones a public payer is charged with protecting.
CMS exists to serve beneficiaries. Its mandate is to protect patients, not programs or professions. Where a requirement principally constrains competition, restricts access, or entrenches incumbents without corresponding patient benefit, it should be removed. Politics over patients.
The solo TAVR operator is not a threat to patients. It is the means of reaching them. Hardly unarmed: percutaneous rescue, disciplined case selection, a defined transfer network.
CMS came some of the way. They didn't have the courage to do the right thing and patients will pay the price.
doi.org/10.1016/j.jcin.2026.…
@JACCJournals @SCAI @ACCinTouch @TCTMD @CRFheart @STS_CTsurgery @MayoClinicCV
@rajivxgulati @SVRaoMD @drroxmehran @AjayKirtaneMD @mmamas1973 @rwyeh @adnanalkhouli @mirvatalasnag @jaygirimd @tjsimard @PietroDiSantoMD @OmarARazek @mandeep_mayo @willsuh76 @EleidMack @ChetRihal @MayraGuerreroMD @AbdullahAlabcha @aelsab @evandrofilhobr @Mahmoud_Ismayl @lamelaspablo #TAVR #TAVI
Luai Madanat, MD retweeted
Sharing the ONE LINER highlights from all the clinical trials presented at #ESCCongress2026 across all spectrum of cardiology 🫀⭐️! So many outstanding IC trials 🤩Congratulations @escardio for a phenomenal advancement of science to next level! 👏 ♥️ #FIT @ESC_Journals @ACCinTouch @NEJM @JAMACardio @JACCJournals @TCTMD @TheLancet @BeaumontIC @RyanMadderMD @IvanHansonMD @amrabbasmd @SimonDixonMBChB @AhmadJabri8
Luai Madanat, MD retweeted
🎙️ CT-Guided PCI: The Imager-Interventionalist Partnership
In Episode 13 of The Coronary Corner, @RyanMadderMD & Michael Gallagher discuss how imaging and interventional teams can partner to build a CT-guided PCI program—from FFR-CT to procedural planning with PCI Navigator.
“Don’t stop at stenosis severity—think about physiology, plaque burden, calcium distribution, and lesion length.”
▶️ YouTube: youtube.com/watch?v=MmQFI3tD…
🎧 Spotify: open.spotify.com/episode/7qf…
Luai Madanat, MD retweeted
NEW 2026 #ESCGuidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA) 👇
ow.ly/jI4f50ZGocP
#ESCCongress
Luai Madanat, MD retweeted
So DELIGHTED to share this news. Genuinely no one more deserving or effective. JACC family are very fortunate. Congratulations Mohamad! @adnanalkhouli @MayoClinicCV @MayoClinic
We’re pleased to announce Dr. Mohamad Alkhouli (@adnanalkhouli) as the next editor-in-chief of #JACCINT. He brings global expertise in interventional cardiology, CV research, and 10+ years of editorial leadership. 👏👏👏
Learn more about him here: bit.ly/4gItbFi
Luai Madanat, MD retweeted
A coronary CTA–derived MIB score (morphology, inflammation, burden) tracked OCT-defined plaque vulnerability in 1,038 plaques. Patients with ≥1 untreated high-MIB lesion had 15.3% vs 4.4% events at 31 months. jacc.org/doi/10.1016/j.jcmg.…
#JACCIMG #yesCCT
Luai Madanat, MD retweeted
Clopidogrel, ticagrelor or prasugrel after PCI? A question every operator answers daily.
A new systematic review and network meta-analysis in JAMA Cardiology (1 July 2026) pools 15 randomised trials and 48,904 patients to rank the three oral P2Y12 inhibitors. 1/7
Luai Madanat, MD retweeted
🫀How do you restore side branch flow after covered stent implantation for coronary perforation?
Diluka Premawardhana et al. present a bailout strategy using covered stent fenestration and TAP stenting.
Read the case: brnw.ch/21x4uvL
#BifurcationPCI #CardioEd
Luai Madanat, MD retweeted
🚨 Check out our recent comprehensive review 📝 on Balloon-Expandable TAVR 🫀@Cardio_Clinics
#Cardiology #CardioEd #ACC @TAVRBot @AhmadJabri8 @PedroMDMSc
interventional.theclinics.co…











































